KRAS and neuroblastoma: All together, these data demonstrate that SETD8 inhibition via SGSS05-NS3 treatment impairs NB cell viability, induces a p53-dependent and caspase-mediated cell death, restoring p53 proapoptotic and growth arrest functions.